The history of GLP peptides — glucagon-like peptides — is one of the most compelling narratives in modern biochemistry. What began as a curiosity about gut-derived hormones in the early 20th century has evolved into one of the most intensely studied areas of metabolic and gastrointestinal peptide research. Understanding where these molecules came from, and how scientific interest in them developed, provides crucial context for researchers working with GLP-1, GLP-2, and GLP-3 analogs today.
From the identification of the proglucagon gene to the characterization of individual peptide fragments and their distinct receptor interactions, the GLP research timeline spans nearly a century of incremental discovery. Each chapter added new mechanistic insight — revealing how a single precursor protein could give rise to multiple bioactive peptides with dramatically different physiological roles. This guide traces that journey in detail.
Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied.
GLP-3 (R) 60MG — Research-Grade Reference Material GLP-3 (R) 60MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
GLP-1 (S) 10MG
$55.00$41.25 with 1st order
GLP-1 (S) 20MG
$125.00$93.75 with 1st order
MOTS-C - 40MG
$135.00$101.25 with 1st order
VIP - 10MG
$65.00$48.75 with 1st order
Frequently Asked Questions
What does GLP stand for in peptide research?
GLP stands for glucagon-like peptide. These are bioactive peptides derived from the proglucagon precursor protein, encoded by the GCG gene. Research has identified multiple GLP fragments — including GLP-1, GLP-2, and GLP-3 — each with distinct receptor binding profiles and areas of scientific investigation.
When was GLP-1 first discovered?
GLP-1 was first characterized in the early 1980s following the cloning and sequencing of the proglucagon gene. Researchers identified that proglucagon was processed differently in intestinal L-cells versus pancreatic alpha cells, yielding distinct peptide fragments including GLP-1 and GLP-2.
What is the proglucagon gene and why is it important to GLP research?
The proglucagon gene (GCG) encodes a precursor protein called proglucagon, which is cleaved by different enzymes in different tissues. In the pancreas, it primarily yields glucagon. In intestinal L-cells and the brainstem, tissue-specific processing yields GLP-1, GLP-2, and other peptide fragments. This differential processing is central to understanding GLP peptide biology.
What is the incretin effect and how does it relate to GLP history?
The incretin effect describes the observation that oral glucose triggers a greater insulin response than intravenous glucose — implying gut-derived factors were stimulating insulin release. Research in the 1960s and 1970s attempted to identify these factors. GLP-1 was later confirmed as one of the primary incretin hormones, linking gut hormone research directly to GLP peptide science.
How does GLP-2 differ historically from GLP-1 in research focus?
While GLP-1 research rapidly focused on metabolic and pancreatic signaling after its discovery, GLP-2 initially received less attention. Its role as a potent intestinotrophic factor — stimulating intestinal growth and repair — was not characterized until the mid-1990s. Research into GLP-2 analogs for intestinal biology followed separately from the metabolic focus of GLP-1 science.
What is GLP-3 and when did research interest in it emerge?
GLP-3 refers to a less-characterized peptide fragment also derived from proglucagon processing. Research interest in GLP-3, particularly retatrutide-related analogs, emerged significantly in the 2010s and 2020s as researchers sought to understand triple-receptor agonism involving GLP, GIP, and glucagon receptor pathways.
Why are GLP peptides considered important in metabolic research?
GLP peptides interact with receptors involved in glucose homeostasis, appetite regulation, gut motility, and cellular energy signaling. Their study spans endocrinology, gastroenterology, and neuroscience — making them a broad platform for investigating metabolic and physiological processes in preclinical models.
Where can researchers source GLP peptides for laboratory study?
Research-grade GLP peptides including GLP-1, GLP-2, and GLP-3 analogs are available from specialized peptide suppliers. SourcePeptides.co carries multiple GLP variants for laboratory research applications.
Early Gut Hormone Research: The Foundation (1900s–1960s)
The intellectual roots of GLP peptide research stretch back to the earliest days of endocrinology. In 1902, British physiologists William Bayliss and Ernest Starling discovered secretin — a hormone released from the small intestine that stimulated pancreatic secretion. This landmark finding established the concept of gut-derived hormones influencing distant organs, and introduced the word “hormone” to scientific vocabulary. It was the conceptual seed from which all GLP research would eventually grow.
GLP-3 (R) 60MG — Research-Grade Reference Material GLP-3 (R) 60MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
GLP-1 (S) 10MG
$55.00$41.25 with 1st order
GLP-1 (S) 20MG
$125.00$93.75 with 1st order
MOTS-C - 40MG
$135.00$101.25 with 1st order
VIP - 10MG
$65.00$48.75 with 1st order
By the 1920s, the discovery and isolation of insulin generated enormous scientific interest in pancreatic signaling. Researchers began to appreciate that the gut and pancreas were in constant biochemical dialogue. The next major milestone came in 1948, when studies on glucagon — a pancreatic peptide with opposing effects to insulin — established the glucagon-insulin axis as a fundamental metabolic regulatory system. Glucagon would later prove to be the closest structural relative of the GLP family.
Throughout the 1950s and 1960s, the field of gastrointestinal endocrinology expanded rapidly. Researchers identified numerous gut-derived peptides including gastrin, secretin, cholecystokinin, and gastric inhibitory polypeptide (GIP). Each discovery reinforced the idea that the intestinal mucosa was not merely an absorptive surface — it was an active endocrine organ capable of sophisticated hormonal signaling. This period laid the conceptual infrastructure that would eventually make GLP peptide biology legible.
The Incretin Hypothesis
A pivotal observation during the 1960s would directly catalyze GLP research decades later. Researchers noted that oral glucose administration produced a significantly larger insulin secretory response than an equivalent amount of glucose delivered intravenously. This disparity implied that the gut was releasing insulin-stimulating factors in response to food — factors that were absent when glucose bypassed the gastrointestinal tract entirely. Scientists named these hypothetical molecules “incretins,” from the phrase “intestinal secretion of insulin.”
The hunt for incretins became one of the defining quests of gastrointestinal endocrinology through the 1970s. GIP (gastric inhibitory polypeptide, later renamed glucose-dependent insulinotropic polypeptide) was the first candidate identified. But researchers suspected additional incretin factors remained undiscovered — a suspicion that would prove well-founded once the proglucagon gene was sequenced.
The Proglucagon Gene: A Single Source, Multiple Peptides (1980s)
The molecular revolution of the 1980s transformed GLP research entirely. In 1982 and 1983, independent research groups in Canada and Denmark successfully cloned and sequenced the proglucagon gene (GCG). The gene encoded a 160-amino-acid precursor protein — proglucagon — that contained not just the glucagon sequence, but also two additional glucagon-like sequences embedded in its C-terminal region. These sequences were designated glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2).
The implications were immediately significant. Here was a single gene producing a precursor that could be differentially processed in different tissues. In pancreatic alpha cells, the enzyme prohormone convertase 2 (PC2) cleaved proglucagon primarily into glucagon. But in intestinal L-cells — and later confirmed in brainstem neurons — a different enzyme, prohormone convertase 1/3 (PC1/3), cleaved proglucagon into GLP-1 and GLP-2, along with other fragments including glicentin and oxyntomodulin. This tissue-specific processing mechanism became known as differential proglucagon processing and remains a cornerstone of GLP biology.
Characterization of GLP-1 as an Incretin
Following the gene sequencing work, researchers moved quickly to characterize the biological activity of GLP-1. Early studies demonstrated that GLP-1 potently stimulated insulin secretion from pancreatic beta cells — and crucially, did so in a glucose-dependent manner. Unlike glucagon, which raised blood glucose, GLP-1 enhanced insulin release only when glucose was present, providing an elegant safety mechanism against hypoglycemia. By the late 1980s, GLP-1 had been confirmed as the second major incretin hormone alongside GIP, and arguably the more potent of the two.
Research groups also identified that the biologically active form of GLP-1 in the circulation was a truncated version — GLP-1(7-36) amide — rather than the full proglucagon-derived sequence. This finding highlighted the importance of post-translational processing in generating bioactive GLP peptides and opened new lines of inquiry into the enzymes responsible for their activation and degradation, particularly dipeptidyl peptidase-4 (DPP-4).
GLP-2 Research Emerges: Intestinal Biology in Focus (1990s)
While GLP-1 research in the 1980s and early 1990s was dominated by metabolic and pancreatic investigations, GLP-2 took a different path. Initial studies struggled to identify a clear receptor or potent biological activity for GLP-2, and it remained relatively understudied for the first decade after its discovery. That changed dramatically in 1996 when a landmark study by Daniel Drucker and colleagues at the University of Toronto demonstrated that GLP-2 was a potent intestinotrophic factor — meaning it stimulated intestinal growth and enhanced mucosal integrity.
The 1996 findings showed that GLP-2 administration in rodent models significantly increased small intestinal mass, villus height, and crypt depth. The GLP-2 receptor (GLP-2R) was subsequently identified and cloned, confirming that GLP-2 operated through a distinct receptor system entirely separate from the GLP-1 receptor. This divergence in receptor biology reinforced the idea that proglucagon-derived peptides, despite their shared origin, had evolved to serve quite different physiological niches.
Throughout the late 1990s, GLP-2 research expanded into intestinal inflammation, barrier function, and nutrient absorption. Preclinical models began exploring whether GLP-2’s intestinotrophic properties could be harnessed to study short bowel conditions and mucosal repair. Teduglutide, a GLP-2 analog with enhanced stability, was developed as a research tool and later became a subject of extensive clinical investigation.
DPP-4 Inhibition, Receptor Agonism, and Analog Development (2000s)
By the early 2000s, GLP peptide research had matured enough to generate significant interest in developing analogs with improved pharmacokinetic profiles. Native GLP-1 has a plasma half-life of only one to two minutes, rapidly degraded by the enzyme DPP-4. This instability made native GLP-1 impractical for sustained experimental use and drove research toward two complementary strategies: DPP-4 inhibitors that prevented degradation, and structurally modified GLP-1 analogs resistant to enzymatic cleavage.
Exendin-4, a GLP-1 receptor agonist isolated from Gila monster venom and sharing approximately 53% sequence homology with human GLP-1, emerged as a key research tool during this period. Its natural resistance to DPP-4 degradation made it a useful model compound for studying sustained GLP-1 receptor activation. Liraglutide, a fatty-acid-conjugated GLP-1 analog with a 13-hour half-life, was developed shortly after and became one of the most extensively characterized GLP-1 receptor agonists in the research literature.
Research during the 2000s also greatly expanded understanding of GLP-1’s central nervous system effects. GLP-1 receptors were identified in the hypothalamus, brainstem, and reward-related brain regions, suggesting roles in appetite regulation and energy homeostasis beyond pancreatic signaling. This neurological dimension of GLP-1 biology opened entirely new research directions that continue to be actively investigated.
The Rise of Multi-Receptor Agonism and GLP-3 Research (2010s–Present)
As understanding of individual GLP receptors deepened, researchers began exploring whether simultaneous activation of multiple receptor pathways might produce synergistic effects in metabolic models. This led to growing interest in dual and triple agonist compounds targeting GLP-1, GIP, and glucagon receptors — a research paradigm sometimes described as “polyagonism.”
It is in this context that GLP-3 research gained significant momentum. GLP-3 analogs, including retatrutide (a triple GLP-1/GIP/glucagon receptor agonist), emerged as subjects of intense preclinical and early-stage investigation. The rationale was that combining GLP-1’s insulinotropic and anorexigenic properties with glucagon’s thermogenic and lipolytic effects might produce distinct metabolic profiles compared to single-receptor agonism. Retatrutide’s development catalyzed a new sub-field of GLP research examining how receptor combination ratios affected energy balance outcomes in animal models.
Simultaneously, advances in structural biology — including cryo-electron microscopy resolution of GLP receptor complexes — provided unprecedented insight into how these peptides engaged their receptors at the molecular level. This structural knowledge has enabled researchers to design more precise analogs with tailored receptor selectivity profiles, representing a major evolution from the early days of simply characterizing proglucagon cleavage products.
GLP Peptides in the Context of Longevity and Inflammation Research
The most recent chapter in GLP peptide history involves their expanding role in research areas beyond classic metabolic biology. Studies have investigated GLP-1 receptor signaling in the context of neuroinflammation, with preclinical models examining whether GLP-1 receptor activation modulates microglial activity and neuronal survival. Separately, GLP-2’s role in gut barrier integrity has generated research interest in inflammatory bowel models, examining whether GLP-2 receptor signaling could modulate intestinal permeability and mucosal immune responses.
MOTS-c and other mitochondrial peptides have also been studied alongside GLP pathways, as researchers seek to understand intersections between mitochondrial signaling and incretin biology in the context of cellular energy regulation. This integrative approach — studying GLP peptides not in isolation but in relation to broader cellular signaling networks — reflects the maturation of the field from its early, organ-centric focus.
Where These Fit in Your Research Library
For researchers building a GLP-focused research library, SourcePeptides.co offers the full range of GLP peptide analogs studied across this historical timeline:
- GLP-1 (S) 20MG — for incretin and metabolic signaling research
- GLP-2 (T) 45MG — for intestinal biology and mucosal integrity models
- GLP-3 (R) 60MG — for multi-receptor agonism and metabolic research
- GLP-3 (R) 10MG — entry-level quantity for preliminary GLP-3 studies
For a complete overview of available research compounds, browse the full catalog at SourcePeptides.co.
Final Takeaway
The history of GLP peptides is a story of scientific accumulation — each decade adding new layers of mechanistic understanding to what began as a simple observation about gut-stimulated insulin release. From Bayliss and Starling’s discovery of secretin in 1902, through the cloning of the proglucagon gene in 1982, to today’s multi-receptor agonist research programs, GLP peptide science has continuously expanded its scope and sophistication.
For researchers today, this historical context matters. Understanding that GLP-1 and GLP-2 share a common precursor but engage entirely different receptor systems — and that GLP-3 analogs represent a more recent effort to exploit polyagonism — provides essential framework for designing rigorous experimental protocols. The GLP field remains one of the most active frontiers in peptide research, with each new structural and mechanistic discovery opening further investigative possibilities.
Sources & Further Reading
- Drucker DJ — “The biology of incretin hormones” — Cell Metabolism (2006)
- Drucker DJ et al. — “Glucagon-like peptide 2 stimulates postprandial metabolic and nutrient absorption in association with intestinal and pancreatic growth” — Am J Physiology (1996)
- Bell GI et al. — “Hamster preproglucagon contains the sequence of glucagon and two related peptides” — Nature (1983)
- PubMed Search — Retatrutide GLP triple receptor agonist research
- Holst JJ — “The physiology of glucagon-like peptide 1” — Physiological Reviews (2007)
